U.S. pharmaceutical markets : expenditures, health insurance, new products and generic prescribing from 1960 to 2016
Year of publication: |
2020
|
---|---|
Authors: | Lu, Z. John ; Comanor, William S. ; Cherkas, Elliot ; Phillips, Llad |
Published in: |
International journal of the economics of business. - Abingdon : Carfax, ISSN 1466-1829, ZDB-ID 1477695-9. - Vol. 27.2020, 1, p. 1-26
|
Subject: | generics | Granger causality | innovations | Insurance | pharmaceutical expenditures | USA | United States | Arzneimittel | Pharmaceuticals | Gesundheitskosten | Health care costs | Innovation | Pharmaindustrie | Pharmaceutical industry | Krankenversicherung | Health insurance | Generika | Generic drugs | Arzneimittelmarkt | Pharmaceutical market | Kausalanalyse | Causality analysis | Schätzung | Estimation |
-
Should pharmaceutical costs be curbed?
Brekke, Kurt R., (2013)
-
Determinants of generic substitution in the Czech Republic
Votapkova, Jana, (2016)
-
Implementing personalized medicine with asymmetric information on prevalence rates
Antoñanzas Villar, Fernando, (2016)
- More ...
-
Strategic pricing of new pharmaceuticals
Lu, Z. John, (1998)
-
Strategic Pricing Of New Pharmaceuticals
Lu, Z. John, (1998)
-
The impact of income and family structure on delinquency
Comanor, William S., (2002)
- More ...